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years of diagnosis was estimated to be about 28.7 million in
2008 [1]. Many must cope with the long-term effects of
treatment, which can affect health-related quality of life
[2,3]. These issues need to be addressed in a systematic
manner in order to enhance the participation of cancer
survivors in society and reduce healthcare costs. Side-
effects and quality of life in long-term survivors after
radiotherapy are not well researched and the data are rarely
collected in a systematic manner in routine follow-up. Also,
studies investigating side-effects can be difficult to compare
because of the use of different toxicity reporting systems
and a lack of pretreatment data, which is important to
ensure that side-effects are related to radiotherapy rather
than other underlying health problems [4]. Predictive
models of radiotherapy toxicity require cross-centre vali-
dation for widespread clinical implementation [5]. Genetics
is important, but no biomarker has been validated for
clinical use. Predictive model research has the potential to
not only improve quality of life, but also to increase survival,
for example by using isotoxic strategies [6], and to decrease
healthcare costs with a more rational use of expensive
medical technology such as proton therapy [7].Author for correspondence: C. West, University of Manchester, Christie
Hospital, Wilmslow Road, Manchester M20 4BX, UK.
E-mail address: Catharine.west@manchester.ac.uk (C. West).
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0936-6555/ 2014 The Royal College of Radiologists. Published by Elsevier Ltd.The REQUITE Project
REQUITE is funded by the European Union through its
Seventh Framework Programme. The objectives of the
project are to: (i) carry out a multicentre, cohort study
collecting blood samples, epidemiology and treatment data,
longitudinal side-effect and quality of life data (before and
after treatment, years 1 and 2); (ii) produce a centralised
database and biobank of DNA for 5300 patients; (iii) vali-
date published biomarkers of radiosensitivity; (iv) validate
clinical predictors of radiotherapy toxicity and incorporate
biomarker data; (v) design interventional trials to reduce
long-term side-effects; (vi) provide a resource for dissemi-
nation and exploitation to the radiotherapy community. The
project focuses on cancers of the breast, lung and prostate.Questionnaires for Collecting Patient-
reported Quality of Life and Toxicity Data
after Radiotherapy
Patient-reported outcomes of health-related quality of
life and toxicity are different, but can provide comple-
mentary information [8]. The European Organization for
Research and Treatment of Cancer (EORTC) quality of life
questionnaires have been translated and validated intoAll rights reserved.
C. West et al. / Clinical Oncology 26 (2014) 739e74274081 languages. However, quality of life is a subjective
measure that is affected by a person’s ability to adapt to
adversity, and the questionnaires have diverse domains
that are not specific for radiotherapy (e.g. social support,
spirituality). The side-effect end points that are most
important for radiotherapy are irreversible and show a
radiation dose response, such as change in breast
appearance [9], pneumonitis [10] and rectal bleeding and
faecal incontinence [11].
Questionnaires were developed to enable the collection
of patient-reported toxicity data after radiotherapy using
the late effects in normal tissues (LENT) scales for patients
with gynaecological [12] or prostate [13] cancer. The ques-
tionnaires were revised to collect CTCAEv3 data, which
incorporated LENT items, for patients with female [14] and
male [15] pelvis cancers and produced for head and neck
cancer [16]. The questionnaires were validated to check for
reliability, compliance and acceptability and were freely
available [17]. The female pelvis questionnaire was trans-
lated into Afrikaans, Hindi, Marathi and Portuguese for use
in an international trial.Further Development of Patient-reported
Toxicity Questionnaires for the REQUITE
Study
A patient-reported toxicity questionnaire is not being
used for breast cancer patients because the items are
covered in healthcare professional-reported toxicity and in
quality of life tools. A lung questionnaire [18] was revised
via consultationwith REQUITE investigators. The previously
developed and validated male pelvis questionnaire was
used. Both questionnaires were translated into multiple
languages. The following procedures were followed for the
lung andmale pelvis questionnaires: (i) two native speakers
(American, Dutch, French, Flemish, German, Italian, Span-
ish) translated the English questionnaires independently;
(ii) translations were merged into a single forward trans-
lation by a third person and any discrepancies resolved via
discussion (no disagreements were identified during this
process that would have required use of alternativewording
for resolution by backward translation); (iii) two native
English speakers independently back translated the ques-
tionnaires into English and a single back-translated version
was sent to an independent reviewer; (iv) differences were
itemised and resolved via discussion; (v) questionnaires
were tested in 10e15 patients in each country and patients
asked to complete a short questionnaire asking whether
any questions were confusing or embarrassing (none was
identified). These validated questionnaires are available at
www.requite.eu.REQUITE Observational Study, Database
and Biobank
The target recruitment is 5300 patients with breast, lung
or prostate cancer. The primary end points are change inbreast appearance at 2 years measured using photographs,
pneumonitis at 1 year and rectal bleeding at 2 years. The
primary end points were selected because they show radi-
ation dose-response relationships. Patients are being
recruited in centres in Belgium, France, Germany, Italy, the
Netherlands, Spain, UK and USA. The initial phase of the
project started in October 2013, with the first patient
recruited at the Icahn School of Medicine at Mount Sinai on
10 April 2014. During the first 6 months of the project, work
focused on producing standardised case report forms for
collecting data, including health professional and patient-
reported toxicity using the CTCAEv4 system. Quality of life
is being assessed using thewell-validated EORTC forms. The
case report forms are available on the REQUITE website.
CentralisedDNAextraction and biobanking ismanaged at
theUniversity ofManchester [19,20]. A second blood sample
is stored locally for future RNA analysis. The centralised
database with electronic case report forms for healthcare
professionals and patient questionnaires is managed by the
University of Leicester [21,22]. The databasewill store breast
photographs, full three-dimensional dosimetric distribu-
tions in DICOM format and dose-volume histogram files. All
datawill be anonymised for use by researchers, and patients
are asked to consent to future sharing of anonymised data,
including across international borders.Validating Predictive Models
A number of factors influence the development of
radiotherapy toxicity [23]. These factors emerged from:
analysis of clinical trials where long-term toxicity data were
collected; generally small studies set up to investigate long-
term side-effects; or retrospective studies that focused on
severe effects that are reported in patients’ notes. The ra-
diation dose and the volumes of normal tissue irradiated are
obviously important. There is also good evidence that
toxicity is affected by: use of additional treatment (surgery,
chemotherapy and hormones), comorbidities such as dia-
betes, older age, smoking and genetic variation.
In recent years, with an increase in data collected,
models have been developed to attempt to predict before
the start of treatment patients at risk of long-term side-
effects [11]. These emerging models require cross-centre
validation to underpin widespread clinical implementa-
tion. There is an increasing number of datasets available for
validation, but they are variable in terms of the data
collected. The REQUITE consortium is accessing existing
datasets to validate and/or improve existing clinical models.
The prospectively collected standardised data will be used
for final validation of the models. The models will be made
available via publication in scientific journals and on open
source websites (e.g. www.predictcancer.org).Biomarkers of Radiation Toxicity
The observational study will also allow for the vali-
dation of developing biomarkers. Genetics influences a
C. West et al. / Clinical Oncology 26 (2014) 739e742 741patient’s risk of developing side-effects and a number of
assays/approaches have been explored to assess a pa-
tient’s sensitivity to radiation. None has been validated
for clinical use. The samples collected in REQUITE will
allow for validation of the most promising biomarkers/
approaches. Recently the first replicated genetic associa-
tions for adverse reactions to radiotherapy were reported
[24]. These should improve predictive models. Central-
ised DNA extraction and storage will facilitate genotyping
later in the project. A flow cytometry method for
assessing radiation-induced lymphocyte apoptosis shows
promise, with high toxicity after radiotherapy associated
with low levels of radiation-induced apoptosis in several
independent studies [25]. Three REQUITE centres will
carry out the assay with early work focusing on cross-
centre standardisation and establishing standardised
operating procedures, which will be made available on
the REQUITE website. The biorepository will allow for
assessment of other promising biomarkers, such as RNA
profiles (PAXgene tube collected sample) and mitochon-
drial DNA [26].Summary
REQUITE is using standardised forms and question-
naires, which are available for data collection in other
studies. The centralised resource will be accessible to
investigate relationships between different toxicity end
points and quality of life and ways to identify better
dosimetric predictors of toxicity. Deasy et al. [27] high-
lighted that the way to accelerate progress in improving
radiotherapy toxicity predictive models is: ‘to begin
storing high-quality datasets in repositories’ so that ‘data
could then be pooled, greatly enhancing the capability to
construct predictive models that are more widely appli-
cable and better powered to accurately identify key
predictive factors’. The REQUITE project addresses the
need for data pooling. Of course, the long-term goal of
predictive model/assay research is to individualise cancer
treatment, which will need decision aids for both radia-
tion oncologists and their patients [28], including infor-
mation on an individual’s likely tumour response and
their risk of side-effects. Widespread implementation will
require a high level of evidence for benefit (e.g. from
randomised trials), including cost-effectiveness and
medico-legal issues will need to be addressed (e.g. CE
marking, Food and Drug Administration approval). High-
quality datasets from multicentre studies of routine
cancer patients are essential to underpin progress in
predictive model research.References
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